J Clin Oncol: The prognostic results of extended follow-up as a first-line treatment for broad-stage small cell lung cancer (IMpower133 trial)

The IMpower133 trial was a randomized, double-blind Phase I/III study that found that the anti-PD-L1 antibody atojutin-added carbaptin and etoposide (CP/ET) combined as a first-line (1L) treatment for broad-stage small cell lung cancer (ES-SCLC) significantly extended the overall survival (OS) and progressive survival (PF) of patients with placebo-CP/ET therapy.
this paper reports on the trial's updated OS, disease progression patterns, safety, and exploratory biomarkers (PD-L1, blood tumor mutation load (bTMB).
The trial divided untreated ES-SCLC patients into two groups and, on the basis of receiving CP-ET treatment, combined atoju monoantigen (1200 mg IV, day 1) or placebo treatment, a 21-day course of treatment with a total of 4 courses, and then maintained treatment with atropules or placebos until there was an impatient toxicity, disease progression, or loss of clinical benefits.
end points are PFS and OS.
201 patients in the prognostic atoju monoantigroup and 202 in the placebo group.
the latest analysis, OS mid-level follow-up 22.9 months, a total of 302 deaths occurred.
12.3 months and 10.3 months, respectively, in the Atoju monoantigroup and placebo group (risk ratio of 0.76, 95% CI 0.60-0.95, p=0.0154), respectively).
at 18 months, 34 percent of patients in the atoju monoantigroup and 21 percent in the placebo group survived, respectively.
effect of PD-L1 status on prognostication regardless of PD-L1 immunohistification or bTMB status, patients can benefit from additional atoju monotherapy.
In summary, the addition of atoju monoantigen as a first-line treatment for ES-SCLC patients in CP/ET solutions has demonstrated the potential of the program as a new standard treatment by showing improved OS and toned safety in the analysis of extended follow-up.
analysis suggests that the treatment benefits of the programme are independent of biomarker status.